SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease.
Kim SR, Lee SG, Kim SH, Kim JH, Choi E, Cho W, Rim JH, Hwang I, Lee CJ, Lee M, Oh CM, Jeon JY, Gee HY, Kim JH, Lee BW, Kang ES, Cha BS, Lee MS, Yu JW, Cho JW, Kim JS, Lee YH. · 2020
Read SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. by Kim SR, Lee SG, Kim SH, Kim JH, Choi E, Cho W, Rim JH, Hwang I, Lee CJ, Lee M, Oh CM, Jeon JY, Gee HY, Kim JH, Lee BW, Kang ES, Cha BS, Lee MS, Yu JW, Cho JW, Kim JS, Lee YH. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7195385.txt.
Introduction
Kim and co-authors test how a diabetes drug class calms a harmful immune alarm called the NLRP3 inflammasome. Their study appeared in Nature Communications. SGLT2 inhibitors cut heart events in type 2 diabetes, but the reason was unclear. Inflammasome activity drives interleukin-1 beta release, which feeds artery disease and heart failure. The team treated high-risk patients for 30 days.
Patients received either empagliflozin or a sulfonylurea drug. Both lowered blood sugar about equally. Only the SGLT2 drug reduced inflammasome activation in patient macrophages. Ketone bodies and lower insulin seemed to mediate the effect. The authors propose this calming action helps explain the heart benefits. The work links a diabetes drug to immune control.
Catalog record
| CREATOR | Kim SR, Lee SG, Kim SH, Kim JH, Choi E, Cho W, Rim JH, Hwang I, Lee CJ, Lee M, Oh CM, Jeon JY, Gee HY, Kim JH, Lee BW, Kang ES, Cha BS, Lee MS, Yu JW, Cho JW, Kim JS, Lee YH. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease By So Ra Kim, Sang-Guk Lee, Soo Hyun Kim, Jin Hee Kim, Eunhye Choi, Wonhee Cho, John Hoon Rim, Inhwa Hwang, Chan Joo Lee, Minyoung Lee, Chang-Myung Oh, Justin Y Jeon Published in: Nature Communications DOI: 10.1038/s41467-020-15983-6 ABSTRACT Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular events in humans with type 2 diabetes (T2D); however, the underlying mechanism remains unclear. Activation of the NLR family, pyrin domain-containing 3 (NLRP3) inflammasome and subsequent interleukin (IL)-1β release induces atherosclerosis and heart failure. Here we show the effect of SGLT2 inhibitor empagliflozin on NLRP3 inflammasome activity. Patients with T2D and high cardiovascular risk receive SGLT2 inhibitor or sulfonylurea for 30 days, with NLRP3 inflammasome activation analyzed in macrophages. While the SGLT2 inhibitor’s glucose-lowering capacity is similar to sulfonylurea, it shows a greater reduction in IL-1β secretion compared to sulfonylurea accompanied by increased serum β-hydroxybutyrate (BHB) and decreased serum insulin. Ex vivo experiments with macrophages verify the inhibitory effects of high BHB and low insulin levels on NLRP3 inflammasome activation. In conclusion, SGLT2 inhibitor attenuates NLRP3 inflammasome activation, which might help to explain its cardioprotective effects. Subject terms: Atherosclerosis, Type 2 diabetes INTRODUCTION Cardiovascular disease (CVD) is a major cause of morbidity and mortality in patients with type 2 diabetes (T2D), with a two- to fourfold increase in incidence compared with patients without diabetes1. Diabetes produces an abnormal metabolic state, including chronic hyperglycemia, dyslipidemia, insulin resistance, and inflammation, which can lead to the development of atherosclerosis, a pathologic process implicated in symptomatic CVD events. A large, multiprotein complex oligomerized in the cytoplasm of innate immune cells, known as the NLR family, pyrin domain-containing 3 (NLRP3) inflammasome, is stimulated to secrete pathogenic inflammatory cytokines, specifically interleukin-1β (IL-1β)2. This is involved in the molecular etiology of numerous chronic inflammatory diseases, including diabetes, non-alcoholic steatohepatitis, gout, atherosclerosis, and heart failure2–7. Sodium–glucose cotransporter 2 (SGLT2) inhibitors lower serum glucose by increasing urinary glucose excretion8. The recently published EMPA-REG OUTCOME study demonstrated that, in patients with T2D and high CVD risk, empagliflozin reduced adverse cardiac events by 14%, which resulted in a 38% reduction in cardiovascular (CV) mortality9. It is the first antidiabetic agent that reduced CV events beyond glycemic control. Subsequently, the CANVAS Program also achieved comparable effects with another SGLT2 inhibitor10. The unique action of SGLT2 inhibitors corrects several metabolic and hemodynamic abnormalities that are risk factors for CVD, by decreasing serum glucose, body weight, and blood pressure and by increasing diuresis8. However, other underlying mechanisms to explain the cardioprotective effects of SGLT2 inhibitors are as yet unclear. Based on their pharmacologic profile, SGLT2 inhibitors cause mild increases in serum ketone bodies, i.e., β-hydroxybutyrate (BHB)8. BHB is a convenient carrier of energy from adipocytes to peripheral tissues, particularly in brain, heart, and skeletal muscles during prolonged fasting or exercise11. Beyond acting as a metabolite, BHB has important cellular signaling roles. Youm et al. revealed that BHB suppresses activation of the NLRP3 inflammasome and reduces IL-1β production in macrophages and mice12. However, there is no report of whether increased serum BHB concentration inhibits NLRP3 inflammasome activation in humans. A recent study demonstrated that fasting and refeeding can differentially regulate NLRP3 inflammasome activation in human peripheral blood mononuclear cells (PBMCs)13. This indicates that the dynamic regulation of NLRP3 inflammasome activation can be assessed using human PBMCs. On the basis of the pathogenic effect of the NLRP3 inflammasome on CVD and the therapeutic role of BHB on its inhibition, the present study demonstrates that the SGLT2 inhibitor blocks NLRP3 inflammasome activation by raising circulating levels of BHB in patients with T2D at high CV risk, which could explain their cardioprotective effects. To exclude glucose-lowering effects on inhibition of NLRP3 inflammasome activation, we used an active comparator, namely sulfonylurea instead of placebo. RESULTS Baseline characteristics of study participants Among 88 screened participants, 71 met the inclusion criteria and were randomly assigned to treatment with empagliflozin (SGLT2 inhibitor) or glimepiride (sulfonylurea). Ten participants withdrew prematurely from the trial, which led to 61 participants completing the study (empagliflozin, 29; and glimepiride, 32) (Fig. 1). [Figure: Participant flow diagram.Numbers of participants who were initially screened, underwent random allocation, withdrew, and were included in the final analysis. SGLT2 sodium–glucose cotransporter 2.] Baseline characteristics of the study participants are summarized in Table 1. Participants were matched for demographic and biochemical variables. As metformin is first-line therapy, most participants in both groups were taking it and continued on the same dosage during the study period. Adverse events related to study drugs were uncommon, although discontinuation of study drug occurred once in each group (Supplementary Table 1). [Table: Baseline characteristics of study participants.] Effects of SGLT2 inhibitor on metabolic parameters Despite a similar glucose-lowering effect in the two groups (Table 2 and Fig. 2a), distinct patterns of change in metabolic parameters were observed in the SGLT2 inhibitor group. SGLT2 inhibitor caused a significant increase in fasting serum BHB, ~3.9-fold from baseline (Fig. 2b) and a significant decrease in serum uric acid and fasting serum insulin (Fig. 2c, d, respectively) accompanied by an increase in fasting serum free fatty acid (FFA) (Fig. 2e), while sulfonylurea had no significant effects on these measurements. SGLT2 inhibitor induced significant improvement in insulin sensitivity (Fig. 2f, g), while sulfonylurea led to increased insulin secretion (Fig. 2h). SGLT2 inhibitor significantly decreased body weight, with a mean change of −2.5% (Fig. 2i). [Table: Effects of sulfonylurea and SGLT2 inhibitor on metabolic parameters.] [Figure: Effects of SGLT2 inhibitor and sulfonylurea on metabolic parameters.a–i Changes in metabolic parameters from baseline to end of treatment (sulfonylurea group: n = 32, SGLT2 inhibitor group: n = 29). †Statistical significance for the time × group interaction evaluated by repeat-measures analysis of variance (ANOVA) (Non-normally distributed variables were log transformed for analysis and back transformed for presentation). Data are represented as mean ± SEM or median (interquartile range). Two-sided paired t test or Wilcoxon signed rank test; *P < 0.05, **P < 0.01, and ***P < 0.001 versus baseline. BHB β-hydroxybutyrate, FFA free fatty acid, HOMA-IR homeostatic model assessment of insulin resistance, QUICKI quantitative insulin sensitivity check index, SEM standard error of the mean, SGLT2 sodium–glucose cotransporter 2. Source data are provided as a Source Data file.] SGLT2 inhibitor suppresses NLRP3 inflammasome activation Regarding the primary endpoint of the current study, IL-1β secretion levels were measured from baseline to end of treatment in isolated macrophages after exposure to 2 mM ATP or 0.2 mM palmitate as an NLRP3 trigger, with 0.1 μg/mL LPS priming. In response to ATP stimulation, IL-1β secretion was significantly reduced after both SGLT2 inhibitor and sulfonylurea treatment (3733 ± 360 to 2549 ± 320 pg/mL, P < 0.001; and 3777 ± 485 to 3121 ± 345 pg/mL, P = 0.01, respectively) (Fig. 3a). However, SGLT2 inhibitor showed a greater reduction in IL-1β secretion compared with sulfonylurea (time × group interaction P = 0.002), which remained significant after adjustment for body weight change (time × group interaction P = 0.02). This tendency was potentiated under the condition of inflammasome stimulation by palmitate (time × group interaction P < 0.001, Fig. 3b). To further evaluate metabolic factors associated with changes in inflammasome activity, correlation